Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 4,357.6% in February

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 2,677,258 shares, an increase of 4,357.6% from the January 29th total of 60,060 shares. Based on an average daily volume of 43,066,965 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.6% of the shares of the stock are short sold. Approximately 8.6% of the shares of the stock are short sold. Based on an average daily volume of 43,066,965 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LIMN. Wall Street Zen lowered shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Liminatus Pharma Trading Up 2.8%

NASDAQ LIMN traded up $0.01 on Wednesday, reaching $0.24. 1,682,279 shares of the company were exchanged, compared to its average volume of 13,576,730. The business’s fifty day moving average price is $0.73 and its 200 day moving average price is $1.40. The stock has a market capitalization of $7.42 million and a P/E ratio of -1.99. Liminatus Pharma has a fifty-two week low of $0.21 and a fifty-two week high of $33.66.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.